



Special Track Session 4

Oncology & Theranostics + Dosimetry Committee

Sunday, October 5, 16:45 – 18:15

Session Title

Debate: Routes to Optimized Theranostics: Is 'Dose' Escalation Enough?

Moderators

Daniela Oprea-Lager (Nijmegen, Netherland)

Johannes Tran-Gia (Würzburg, Germany)

Point of view: Targeted radionuclide therapy trials should follow models from drug-based oncology

Françoise Kraeber Bodéré (Nantes, France)

Point of view: Targeted radionuclide therapy trials should follow radiotherapy logic

Jonathan Wadsley (Sheffield, United Kingdom)

Educational Objectives

1. To understand the evolving role of dosimetry in targeted radionuclide therapy
2. To explore how clinical dosimetry can guide trial design and escalation strategies
3. Learn about ongoing initiatives and EANM guidelines

Summary

Clinical dosimetry is increasingly used in the Theranostics domain. This interactive debate explores trial design strategies in targeted radionuclide therapy, focusing on whether treatment escalation should be guided by injected activity or absorbed dose. Experts from nuclear medicine and oncology will share perspectives on how to optimize and personalize RPT, while also considering practical constraints such as clinical workflows and resource availability. The session promotes a collaborative, interdisciplinary discussion rather than a binary "for or against" debate.

Key Words

Targeted Radionuclide Therapy; Oncology; Dosimetry